In our study, we compared the effectiveness of three neoadjuvant targeted therapy strategies (H + Py, trastuzumab plus pyrotinib; H, trastuzumab; HP, trastuzumab plus pertuzumab) based on the same chemotherapy regimen (TC, docetaxel and carboplatin) for HER2-positive early breast cancer. Here, ERBB2 is linked to breast carcinoma.